Recurrent Pregnancy Loss After Two Miscarriages: Which Tests Are Worth Discussing?

The American Society for Reproductive Medicine’s updated 2026 guidance defines recurrent pregnancy loss as two or more pregnancy losses, excluding confirmed molar or ectopic pregnancies, and recognises very early losses confirmed by urine or blood hCG. That definition helps patients seek evaluation rather than wait for an arbitrary sequence. However, the timing and scope of testing still depend on maternal age, pregnancy details, prior imaging, medical conditions and whether any previous loss was tested. A person with one loss plus a strong genetic or medical risk may also warrant an individualised conversation rather than a blanket instruction to wait.

Chromosomal abnormalities in the pregnancy itself are an important cause of early miscarriage. Where tissue can be tested, a genetic analysis may help distinguish a pregnancy-specific chromosomal event from a situation that warrants further family investigation. Results are not always obtainable or conclusive, and sampling decisions require sensitivity to the patient’s circumstances. A specialist should explain whether the test is feasible, how it will be processed and what different outcomes would mean. Sending every couple directly to parental chromosome analysis without considering the history can miss the more useful first question: what was found in the pregnancy?

A uterine cavity assessment may identify a septum, adhesions, retained tissue, a polyp or a fibroid affecting the cavity. Ultrasound and other imaging or hysteroscopic tests may be used depending on the case. These are facility-based investigations, not home blood tests. Finding an anatomical difference does not always mean it caused the miscarriage or must be treated, but it may change management. HomeIVF’s useful role is to coordinate the investigation and ensure previous images and reports reach the reviewing specialist, rather than recommending invasive testing to everyone without first examining the available records.

Thyroid testing can be relevant in particular recurrent-loss scenarios, while other endocrine tests depend on the history and symptoms. Antiphospholipid syndrome testing has specific clinical and laboratory criteria; a single positive antibody result is not enough to establish the diagnosis, and repeat confirmation may be required. Broad inherited-thrombophilia or immune “implantation” panels are not automatically indicated. Patients should ask a direct question before every additional blood test: if this result is positive or negative, what precisely changes about treatment? This protects couples from unnecessary cost, delay and false reassurance from incidental findings.

Parental karyotyping may be discussed when pregnancy-tissue analysis identifies an unbalanced structural rearrangement or when tissue testing was not available and the history supports it. It is not a universal substitute for a thorough history. If a chromosome rearrangement is identified, genetic counselling helps explain recurrence risks and reproductive options; discussions of embryo testing should be specific to the actual genetic finding. Genetic testing raises emotional and family-planning questions, so the report should be explained by the appropriately trained team rather than reduced to “normal” or “abnormal” in a generic portal message.

Patients can begin by uploading dates of prior pregnancies, gestational age at each loss, ultrasound reports, pathology and genetic results, medications, known conditions and previous fertility treatment records. A video review can identify missing evidence before the patient travels. Selected prescribed blood samples may then be collected at home or locally where reliable services exist. Ultrasound, uterine-cavity assessment and procedures remain facility-based. The value is a coherent plan and fewer avoidable trips—not an attempt to diagnose pregnancy loss using a chatbot or unverified tests. Couples should also be offered emotional support; clinical evaluation and grief often run in parallel.

An extensive “immune infertility” panel can include tests with poorly demonstrated value for most recurrent-loss patients. Similar caution applies to inherited thrombophilia testing when there is no specific indication. An incidental abnormality may lead to unnecessary treatment or anxiety without showing why a miscarriage occurred. Ask whether the clinic follows recognised guidelines and what evidence connects the proposed abnormal result to a management decision. The presence of a test on a commercial lab menu is not a clinical reason to order it. One targeted investigation that changes care is worth more than many uninterpretable results.

Recurrent loss affects relationships, work and confidence as well as physical health. Patients may want a partner or support person in the consultation and time to ask questions without rushing into another pregnancy or IVF cycle. It helps to obtain a short written summary: which losses were documented, whether tissue genetics were available, which tests are recommended, which are not, and the planned follow-up. HomeIVF should keep the medical review separate from commercial pressure to purchase a new treatment cycle. A compassionate pathway can be rigorous without making promises about the next pregnancy.

Request a HomeIVF records-based recurrent pregnancy loss review before ordering another large test panel. Clinical advice and availability are subject to review.